These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

929 related items for PubMed ID: 28291655

  • 1. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH, Udell JA, Filion KB.
    Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular safety outcomes of new antidiabetic therapies.
    LeBras MH, Barry AR, Koshman SL.
    Am J Health Syst Pharm; 2017 Jul 01; 74(13):970-976. PubMed ID: 28483748
    [Abstract] [Full Text] [Related]

  • 3. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun 01; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

  • 4. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep 01; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J, Sands M, Burciu C, Reaven P.
    Diab Vasc Dis Res; 2015 May 01; 12(3):154-63. PubMed ID: 25852133
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y, Tsoi MF, Cheung BMY.
    Cardiovasc Diabetol; 2019 Aug 28; 18(1):112. PubMed ID: 31462224
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK, Smith SM, Park H.
    Cardiovasc Diabetol; 2018 Jul 17; 17(1):102. PubMed ID: 30016946
    [Abstract] [Full Text] [Related]

  • 13. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL, Degeeter M, Nuzum DS, Tzefos M.
    Ann Pharmacother; 2013 Apr 17; 47(4):490-505. PubMed ID: 23548652
    [Abstract] [Full Text] [Related]

  • 14. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 17; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Serné EH, van Raalte DH.
    Arterioscler Thromb Vasc Biol; 2016 Oct 17; 36(10):2125-32. PubMed ID: 27562916
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E, Monami M.
    Adv Ther; 2017 Jan 17; 34(1):1-40. PubMed ID: 27844335
    [Abstract] [Full Text] [Related]

  • 18. New Therapeutic Strategies for Type 2 Diabetes CME.
    Yehya A, Sadhu AR.
    Methodist Debakey Cardiovasc J; 2018 Jan 17; 14(4):281-288. PubMed ID: 30788014
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
    Scheen AJ.
    Diabetes Res Clin Pract; 2017 May 17; 127():224-237. PubMed ID: 28402902
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM, Christensen MB.
    Drugs Today (Barc); 2018 Sep 17; 54(9):547-559. PubMed ID: 30303495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.